StockData

Ascentage Pharma Group International vs Ligand Pharmaceuticals

AAPG and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and LGND compare

Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −41.5% for Ascentage Pharma Group International).

Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −216% at Ascentage Pharma Group International.

Ligand Pharmaceuticals scores higher on the StockData Score (6 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGLGND
Size and price
Market cap–$5.9B
Share price$13.14$293.81
Change, 1 year−61.7%46.3%
Change, 5 years–87.3%
Beta (5Y)1.430.84
Employees76747
StockData Score
Total score36 (better)
Valuation score00
Growth score11
Performance score13 (better)
Health score12 (better)
Dividend score00
Valuation
P/E–128×
P/S–23.2×
P/B–6.1×
EV/EBITDA–108×
P/FCF–64.8×
FCF yield–1.5%
Fair value–$55.15
Margin of safety–−433%
Growth
Revenue growth (TTM)−41.5%1.0% (better)
Revenue growth, 5Y average–10.4%
Net income growth (TTM)–5.9%
EPS growth (TTM)–18.7%
Profitability
Gross margin91.5%–
Operating margin–10.1%
Net margin−216%20.3% (better)
FCF margin−209%35.7% (better)
Return on equity−156%5.4% (better)
Return on invested capital–2.6%
Financial health
Debt / equity1.501.17 (better)
Net debt / EBITDA–11.26
Interest coverage–3.1×
Current ratio1.79 (better)1.22
Altman Z-score–3.32
Piotroski F-score–6
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%113%
Held by insiders13.0%2.6%
Insider net buying, 12 months–−$36.5M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.